Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Core Insights - Alto Neuroscience, Inc. is accelerating the development of ALTO-207 for treatment-resistant depression (TRD) following a successful FDA meeting [1] - The company announced a $50 million private placement to support the expanded development of ALTO-207 [1] Company Overview - Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders [1] Financial Aspects - The recent $50 million private placement will facilitate the advancement of ALTO-207 [1]